Impaired Orai1-mediated Resting Ca\(^{2+}\) Entry Reduces the Cytosolic [Ca\(^{2+}\)] and Sarcoplasmic Reticulum Ca\(^{2+}\) Loading in Quiescent Junctophilin 1 Knock-out Myotubes*

In the absence of store depletion, plasmalemmal Ca\(^{2+}\) permeability in resting muscle is very low, and its contribution in the maintenance of Ca\(^{2+}\) homeostasis at rest has not been studied in detail. Junctophilin 1 knockout myotubes (JP1 KO) have a severe reduction in store-operated Ca\(^{2+}\) entry, presumably caused by physical alteration of the sarcoplasmic reticulum (SR) and T-tubule junction, leading to disruption of the SR signal sent by Stim1 to activate Orai1. Using JP1 KO myotubes as a model, we assessed the contribution of the Orai1-mediated Ca\(^{2+}\) entry pathway on overall Ca\(^{2+}\) homeostasis at rest with no store depletion. JP1 KO myotubes have decreased Ca\(^{2+}\) entry, [Ca\(^{2+}\)]\(_{rest}\), and intracellular Ca\(^{2+}\) content compared with WT myotubes and unlike WT myotubes, are refractory to BTP2, a Ca\(^{2+}\) entry blocker. JP1 KO myotubes show down-regulation of Orai1 and Stim1 proteins, suggesting that this pathway may be important in the control of resting Ca\(^{2+}\) homeostasis. WT myotubes stably transduced with Orai1(E190Q) had similar alterations in their resting Ca\(^{2+}\) homeostasis as JP1 KO myotubes and were also unresponsive to BTP2. JP1 KO cells show decreased expression of TRPC1 and -3 but overexpress TRPC4 and -6; on the other hand, the TRPC expression profile in Orai1(E190Q) myotubes was comparable with WT. These data suggest that an important fraction of resting plasmalemmal Ca\(^{2+}\) permeability is mediated by the Orai1 pathway, which contributes to the control of [Ca\(^{2+}\)]\(_{rest}\) and resting Ca\(^{2+}\) stores and that this pathway is defective in JP1 KO myotubes.

In muscle fibers and cultured myotubes, the free cytosolic Ca\(^{2+}\) concentration at rest ([Ca\(^{2+}\)]\(_{rest}\)) is strictly held at a low and narrow range (115 to 125 nM at room temperature) (1, 2). At the same time, the Ca\(^{2+}\) concentration in internal stores and the extracellular space is 10,000 times greater. To achieve this equilibrium, multiple mechanisms are working simultaneously to regulate basal Ca\(^{2+}\) levels.

At least three different mechanisms have been identified to preserve [Ca\(^{2+}\)]\(_{rest}\) in skeletal muscle: (i) a highly abundant sarcoplasmic/endoplasmic reticulum Ca\(^{2+}\) ATPase (SERCA) that recaptures Ca\(^{2+}\) into the SR, (ii) the sarcolemmal Na\(^{+}\)/Ca\(^{2+}\) exchanger, which has a low Ca\(^{2+}\) affinity but high transport capacity to remove Ca\(^{2+}\) from the cytoplasm to the extracellular space, and (iii), the plasma membrane Ca\(^{2+}\) ATPase, which transports Ca\(^{2+}\) from the cytoplasm to the extracellular space with a Ca\(^{2+}\) high affinity but low capacity. Although the first mechanism is most important in the short term, the latter two are critical for long term control. In addition to these “classical” regulatory mechanisms, there is ample evidence for a passive efflux of Ca\(^{2+}\) from the SR (Ca\(^{2+}\) leaks) through the ryanodine-insensitive pathway that also significantly contribute to regulation of [Ca\(^{2+}\)]\(_{rest}\) in skeletal muscle (3).

Despite the strong electrochemical potential that Ca\(^{2+}\) ions have toward the intracellular space at rest, resting Ca\(^{2+}\) entry (R\(_{Ca}\)) is barely detectable due to the virtual impermeability of the cell membrane to Ca\(^{2+}\), and this observation would suggest that extracellular Ca\(^{2+}\) permeability does not contribute to setting [Ca\(^{2+}\)]\(_{rest}\). However, against this suggestion is the fact that a brief removal of extracellular Ca\(^{2+}\) has been shown to cause a decrease of [Ca\(^{2+}\)]\(_{rest}\) in adult skeletal muscle (4). The mechanisms that control Ca\(^{2+}\) entry in muscle cells at rest are not well identified. What is known is that the acute depletion of the intracellular Ca\(^{2+}\) stores, using SERCA inhibitors, results in an increased permeability to extracellular Ca\(^{2+}\) (SOCE) (5, 6). One of the molecular determinants of this phenomenon is Stim1 (stromal interaction molecule 1), which acts as an intraluminal Ca\(^{2+}\) sensor of the SR (7, 8). The high luminal [Ca\(^{2+}\)] in the SR at rest prevents oligomerization of Stim1 monomers, but when luminal [Ca\(^{2+}\)] is lowered, it promotes Stim1 oligomerization and clustering of Stim1 in the endoplasmic reticulum/SR. While in this conformation, Stim1 interacts with Orai1, which is an integral pro-

---

* This work was supported, in whole or in part, by National Institutes of Health/NAMs Grants 2R01AR43140 (to P. D. A.), R01AG28856 (to J. M. and H. T.), and R01HL69000 (to J. M.).
1 Present address: Dept. of Histology and Embryology, Third Military Medical University, Chongqing 400036, China.
2 Present address: Dept. of Anesthesiology, Shengjing Hospital, China Medical University, Liaoning 110004, China.
3 To whom correspondence should be addressed: Dept. of Anesthesiology Perioperative and Pain Medicine, Brigham and Women’s Hospital, 75 Francis St., Boston, MA 02115. E-mail: jmeltit@zeus.bwh.harvard.edu.

---

4 The abbreviations used are: SERCA, sarcoplasmic/endoplasmic reticulum Ca\(^{2+}\) ATPase; SOCE, store-operated Ca\(^{2+}\) entry; JP1 KO, junctophilin 1 knock-out; SR, sarcoplasmic reticulum; R\(_{Ca}\), resting Ca\(^{2+}\) entry; TRPC, canonical transient receptor potential; f.a.u., fluorescence arbitrary units; ANOVA, analysis of variance; NS, no significant difference; RyR1, ryanodine receptor; OAG, 1-oleoyl-2-acetylglycerol.
tein of the plasma membrane (9–11). Support for the interaction of Stim1 and Orai1 being one mechanism for SOCE is found from experiments that show that Orai1 knock-out/knockdown or the expression of dominant negative forms of Orai1 almost completely prevents SOCE despite normal clustering of Stim1 (10–12). Although it has been proposed that Orai1 by itself could be the Ca2+ channel responsible for the SOCE current, the participation of canonical transient receptor potential (TRPC) channels alone or in concert with Orai1 in this process has also been suggested (13–16). In immortal cell lines, it has been shown that an Orai1-dependent mechanism orchestrated with a Ca2+ store sensor works as a feedback loop, which might contribute to keep [Ca2+]rest and the SR Ca2+ stores at normal levels, suggesting a link between SOCE and the control of the resting Ca2+ homeostasis (17).

The membrane system of skeletal muscle is highly organized in triads where the junctional SR and the T-tubule membrane are only ∼10 nm apart. The proximity of these two membranes is critical for the physical coupling between the dihydropyridine receptor and the ryanodine receptor 1 (RyR1) for EC coupling and likewise for the coupling of Stim1 and Orai1 for SOCE (18). Orai1 and several TRPC channels (TRPC1, -2, -3, -4 and -6) are expressed in skeletal muscle as well as in cultured myotubes (18–20), and most of these channels have been localized in or near the triad junction. It is believed that junctophilins (JP1 and JP2) are the specialized proteins in the triad that maintain the proper spatial disposition of the triad membranes (21–23). Decreased expression of JP proteins by knockdown/knock-out strategies has been shown to cause altered triad formation, and this structural alteration is thought to be responsible for the decreased SOCE found in JP1 KO muscle cells (23). However, the mechanism by which the absence of JP1 affects SOCE other than the presumed association with this structural change has not been investigated.

In the current study, we explored the possible failure of Orai1-mediated sarcolemmal Ca2+ entry at rest and the concomitant alterations in the resting Ca2+ homeostasis in JP1 KO skeletal myotubes. Using the Ca2+ entry blocker BTP2 and Orai1 pore mutant (E190Q), we demonstrated that an Orai1-mediated entry pathway at rest is blocked by BTP2 and that this pathway is absent in JP1 KO myotubes. In addition, we show that the Orai1-dependent RCaE is fundamental to maintain levels of physiological [Ca2+]rest in the cytosol and to maintain the Ca2+ content in intracellular stores.

**EXPERIMENTAL PROCEDURES**

**Cell Culture**—WT or JP1 KO myoblasts were plated either on 96-well imaging plates or 35-mm plates in Ham’s F-10 medium (Invitrogen) supplemented with 20% bovine growth serum and 5 ng/ml basic fibroblast growth factor (Thermo Fisher Scientific). The following day, differentiation was started by changing the media to DMEM (Invitrogen) supplemented with 2% heat inactivated horse serum (Sigma).

**Permanent Expression of Orai1 and Orai1(E190Q) in Myoblasts**—Orai1 and Orai1(E190Q) cDNAs cloned into a retroviral expression vector with a bicistronic eGFP expression cassette and puromycin resistance were obtained from Addgene (Cambridge, MA, plasmids 12199 and 21662, respectively). These plasmids were kindly deposited by Dr. Anjana Rao (Harvard Medical School and Immune Disease Institute, Boston, MA) (11). We verified the correct sequence of both inserts and retroviral particles were packaged in HEK 293 helper cells, and myoblasts were infected with either construct at a multiplicity of infection of 5. Cells were allowed to recover for 12 h and then selected with puromycin (0.5 μg/ml) for 1 week. After the selection period, all remaining cells on the plate show the expression of the eGFP marker. An uninfected cell culture did not survive to the selection protocol, and wild type cells were used as controls.

**Double-barreled Ca2+ Microelectrodes and [Ca2+]rest Measurements**—Double-barreled Ca2+-selective microelectrodes were prepared using thin-walled borosilicate glass capillaries with filament (PB150F-4, World Precision Instruments, Sarasota, FL) as described previously (2). They were back-filled first with the neutral carrier ETH 129 (21193 Fluka-Sigma-Aldrich) and then with pCa 7 solution. Each Ca2+-selective microelectrode was individually calibrated as described previously (4), and only those with a linear relationship between pCa 3 and pCa 7 (Nernstian response, 28.5 mV per pCa unit) were used experimentally. After measuring resting [Ca2+]i, all electrodes were then recalibrated, and if the two calibration curves did not agree within 3 mV, data from that microelectrode were discarded. Before starting the studies, we determined by direct calibration that the Ca2+ sensitivity of Ca2+ microelectrodes was not affected by any of the drugs used in the present study.

Microelectrode recordings were performed as described previously (2). Single myotubes were impaled with the double-barreled Ca2+-selective microelectrode, and the potentials were recorded via high impedance amplifier (Duo 773 electrometer, World Precision Instruments, Sarasota, FL). The potential from the 3 m KCl microelectrode (Vm) was subtracted electronically from the potential of the Ca2+ electrode (VCaE), to produce a differential Ca2+-specific potential (VCa) that represents [Ca2+]rest. Vm and VCa were filtered (30–50 KHz) to improve the signal-to-noise ratio and stored in a computer for further analysis.

**Store-operated Ca2+ Entry Measurements**—5 to 6 days after differentiation, the myotubes were loaded with 5 μM Fura2-AM (Invitrogen) for 30 min at 37 °C. After three washes with imaging solution (140 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1 mM CaCl2, 5.5 mM glucose, 10 mM Hepes, pH 7.4), the cells were subjected to a Ca2+ store depletion protocol, incubating the cells in zero Ca2+ solution (140 mM NaCl, 5 mM KCl, 2 mM MgCl2, 5.5 mM glucose, 1 mM EGTA, 10 mM Hepes, pH 7.4) supplemented with 5 mM thapsigargin. After 20 min, the cells were placed on the stage of a TE2000 epifluorescence microscope (Nikon) coupled to a digital acquisition system (Stanford Photonics, Stanford CA). The cells were illuminated at the isosbestic Fura2 excitation wavelength (360 nm), and the fluorescence was measured at 510 nm. Cells were then perfused with zero Ca2+ solution and after 30 s switched to Mn2+-containing solution (140 mM NaCl, 5 mM KCl, 0.5 mM MnCl2, 5.5 mM glucose, 10 mM Hepes, pH 7.4), and the changes in Fura2 fluorescence were monitored.
Resting Ca\(^{2+}\) Entry Measurements—Fura2-loaded myotubes were perfused with imaging solution for 1 min, and then the perfusion system switched to Mn\(^{2+}\)-containing solution for 3 min. Some recordings showed motion artifact due to perfusion switching and to minimize errors in calculating the rate of decrease in Fura2 fluorescence after Mn\(^{2+}\) exposure, the rate was measured when the signal was linear and stable (30 s after solution twitching). To calculate the fluorescence quench rate, the stable part of the signal was fitted to a linear regression (\(y = ax + bx\)). The slope derived is expressed as fluorescence arbitrary units (f.a.u.) per second.

Western Blot Analysis—Membrane vesicle preparation and immunoblotting were prepared from differentiated myotubes. The cells were homogenized in a Polytron cell disrupter in 5 mM imidazole, pH 7.4, 300 mM sucrose supplemented with protease inhibitor (Complete\(^{TM}\), Roche Applied Science) and collected as described previously (24). Proteins were separated using SDS-PAGE and transferred to polyvinylidene difluoride membranes. Expression of specific proteins was assayed by incubation of the membranes with polyclonal antibodies against junctophilin 1 (Zymed Laboratories Inc., San Francisco, CA); junctophilin 2 (Zymed Laboratories Inc., San Francisco, CA); Stim1 (Affinity BioReagents, Golden, CO); Orai1 (AnaSpec, Inc., San Jose, CA); gliceraldehyde-3-phosphate dehydrogenase (FL-335, Santa Cruz Biotechnology, Santa Cruz, CA); TRPC1 (Santa Cruz Biotechnology); and TRPC3, TRPC4, and TRPC6 (Abnova, Walnut, CA).

Sarcoplasmic Reticulum Loading Capacity—Myotube preparations were loaded with 5 \(\mu\)M Fluo-4 AM for 30 min at 37 °C. The myotubes were placed on the stage of a Nikon TE2000 epifluorescence microscope coupled to a digital acquisition system (Stanford Photonics). A filter set with an excitation of 480/30 nm and emission of 535/40 nm was used. The emission signal was acquired at a frequency of 30 frames per second. The amount of SR Ca\(^{2+}\) was estimated by taking the combined area under the curve of three sequential exposures to 20 mM caffeine in Ca\(^{2+}\)-free medium to prevent Ca\(^{2+}\) entry to get the total area under the curve to assess the total amount of Ca\(^{2+}\) released. To estimate the total intracellular Ca\(^{2+}\) store, Fluo-4 AM-loaded myotubes were exposed to the Ca\(^{2+}\) ionophore 4Br-A23187 in Ca\(^{2+}\)-free medium. The area of the released Ca\(^{2+}\) was computed for each myotube type studied.

Statistics—All values are expressed as mean ± S.E., with the numbers in parentheses indicating the number of myotubes tested. Statistical analysis was performed using one-way analysis of variance and Tukey’s test for multiple measurements to determine significance (\(p < 0.05\)).

RESULTS

Effect of BTP2 on \(R_{\text{cat}}\) and SOCE—Ca\(^{2+}\) influx at rest in WT myotubes measured using Mn\(^{2+}\) quench showed a slow decay in Fura2 fluorescence signal after Mn\(^{2+}\) exposure with a rate of \(-0.79 ± 0.08\) (f.a.u)/s \((n = 61)\). Incubation with BTP2 reduced the quench rate by more than half to \(-0.36 ± 0.04\) (f.a.u)/s \((n = 38)\). Interestingly, JP1 KO myotubes had a lower quench rate at rest than WT myotubes \((-0.39 ± 0.02\) (f.a.u)/s \((n = 87)\)), and although BTP2 treatment decreased the rate to \(-0.25 ± 0.04\) (f.a.u)/s \((n = 41)\), this difference was not statistically significant (ANOVA analysis in Fig. 1) from untreated cells.

After a depletion protocol with thapsigargin, WT myotubes showed robust Mn\(^{2+}\) entry, which was strongly affected by 5 \(\mu\)M BTP2 (Fig. 2, left). In contrast, JP1 KO myotubes showed markedly decreased Mn\(^{2+}\) entry compared with WT myotubes; however, the small amount of Mn\(^{2+}\) entry that remained could also be blocked by BTP2 (Fig. 2, right).

![Figure 1](https://example.com/figure1.png)

**FIGURE 1.** Estimation of resting Ca\(^{2+}\) entry \((R_{\text{cat}})\) in WT and JP1 KO myotubes. \(R_{\text{cat}}\) was estimated using the Mn\(^{2+}\) quench technique in myotubes that were not subjected to store depletion as described under “Experimental Procedures.” The arrow shows the time point when the Mn\(^{2+}\)-containing solution was applied by the automatic perfusion system. The rate of fluorescence decay for each individual trace was calculated as the slope of a linear regression. WT and JP1 myotubes were tested in the presence and absence of 5 \(\mu\)M BTP2. Mean ± S.E. is plotted for each condition. *****, \(p < 0.001\); one-way ANOVA.

![Figure 2](https://example.com/figure2.png)

**FIGURE 2.** SOCE in WT and JP1 KO myotubes. SOCE was evaluated by a Mn\(^{2+}\) quench technique in myotubes subjected to store depletion as described under “Experimental Procedures.” The arrow indicates the time point when the perfusion system was switched to a Mn\(^{2+}\)-containing solution. The left panel are the SOCE signals of WT myotubes and the effect of 5 \(\mu\)M BTP2. The right panel shows Mn\(^{2+}\) entry in JP1 KO myotubes in the absence or presence of 5 \(\mu\)M BTP2. Mean traces ± S.E. of at least 20 myotubes are shown.
BTP2 decreases $[\text{Ca}^{2+}]_{\text{rest}}$ in WT but not in JP1 KO Myotubes—$[\text{Ca}^{2+}]_{\text{rest}}$ in WT myotubes was 118 ± 1.5 nM ($n = 19$) and 102 ± 0.7 nM ($n = 12$) in JP1 KO myotubes ($p < 0.001$). In WT myotubes, exposure to 5 $\mu$M BTP2 for 10 min caused a reduction of $[\text{Ca}^{2+}]_{\text{rest}}$ to 94 ± 1.7 nM ($n = 19$) ($p < 0.001$). Similar treatment of JP1 KO myotubes with BTP2 had no effect on $[\text{Ca}^{2+}]_{\text{rest}}$ (100 ± 0.7 nM, $n = 10$, $p = \text{NS}$; Fig. 3).

BTP2 Treatment Partially Depletes Ca$^{2+}$ Stores in WT Myotubes—To estimate the SR Ca$^{2+}$ content in myotubes, we measured cytosolic Ca$^{2+}$ transient induced by three consecutive 20 mM caffeine pulses in Ca$^{2+}$-free medium (Fig. 4, A and B), and the total integral of the three responses was computed. In WT myotubes, the integral was 3.2 ± 0.6 arbitrary units, ($n = 13$), and after treatment with BTP2, it was reduced to 1.3 ± 0.2 a.u. ($n = 16$, $p < 0.01$) (Fig. 4C). In JP1 KO myotubes, the integral was significantly lower than in WT cells (1.2 ± 0.2 a.u., $n = 30$, $p < 0.001$), but pretreatment with BTP2 had no effect on Ca$^{2+}$ release in response to caffeine (1.1 ± 0.2 a.u., $n = 17$, $p = \text{NS}$, Fig. 4C). As a second approach to estimate the intracellular Ca$^{2+}$ content, we exposed the myotubes to the Ca$^{2+}$ ionophore 4Br-A23187 in Ca$^{2+}$-free medium (Fig. 4, D and E). The results were similar to those observed using caffeine. In WT cells, the Ca$^{2+}$ release integral was 9.5 ± 0.9 a.u. ($n = 24$) before and 5.1 ± 0.5 a.u. ($n = 38$, $p < 0.001$) (Fig. 4F) after BTP2 treatment. In untreated JP1 KO myotubes, the Ca$^{2+}$ integral was 4.6 ± 0.3 a.u. ($n = 52$, $p < 0.001$) and BTP2 treatment had no effect (4.0 ± 0.2 a.u., $n = 52$, $p = \text{NS}$, Fig. 4F).

Orai1 and Stim1 Expression Are Decreased in JP1 KO Myotubes—We evaluated the expression of two key proteins involved in Ca$^{2+}$ entry, Stim1 and Orai1, in WT and JP1 KO myotubes. Western blot analysis shows that expression of both Orai1 and Stim1 are significantly decreased in JP1 KO cells (~65 and ~60% decrease, respectively, $n = 5$, $p < 0.01$), whereas the expression of JP2 remained unchanged (Fig. 5).

Expression of Orai1(E190Q) Decreases $R_{\text{CaE}}$ and SR Ca$^{2+}$ Content at Rest—As was expected from previously published studies (12), the expression of the dominant negative form Orai1(E190Q) blocks SOCE in myotubes, whereas Orai1 overexpression does not have any effect (Fig. 6). In addition to the reduction of SOCE associated with overexpression of Orai1(E190Q), $R_{\text{CaE}}$ was also significantly lower ($-0.28 ± 0.02$ f.a.u./s, $n = 52$, $p < 0.01$) compared with Orai1-overexpressing myotubes ($-0.58 ± 0.04$ f.a.u./s, $n = 46$; Fig. 7). After BTP2 pretreatment, the $R_{\text{CaE}}$ in Orai1-overexpressing myotubes, decreased to $-0.31 ± 0.03$ f.a.u./s, $n = 39$ ($p < 0.001$), whereas in Orai1(E190Q), expressing cells were unresponsive to BTP2 ($-0.26 ± 0.03$ f.a.u./s, $n = 39$ ($p = \text{NS}$)). In myotubes overexpressing Orai1, $[\text{Ca}^{2+}]_{\text{rest}}$ was 119 ± 0.6 nM ($n = 20$), and the addition of BTP2 reduces the $[\text{Ca}^{2+}]_{\text{rest}}$ to 95 ± 1.2 nM ($n = 10$, $p < 0.001$). In Orai1(E190Q) myotubes, the $[\text{Ca}^{2+}]_{\text{rest}}$ was 102 ± 1.2 nM ($n = 20$, $p < 0.001$, Fig. 7, right panel) and are refractory to BTP2 treatment ($[\text{Ca}^{2+}]_{\text{rest}}$ 102 ± 1.9 nM, $n = 11$, $p = \text{NS}$, Fig. 7, right panel).

The decrease in $[\text{Ca}^{2+}]_{\text{rest}}$ in myotubes expressing Orai1(E190Q) was accompanied by a significant decrease in total internal store Ca$^{2+}$ content as demonstrated in a drop in the Ca$^{2+}$ integral after exposure to 4Br-A23187 in Ca$^{2+}$-free media to 6.6 ± 0.3 a.u. ($n = 54$, $p < 0.001$) compared with 8.7 ± 0.4 a.u. ($n = 82$) in Orai1-overexpressing myotubes (Fig. 8). BTP2 treatment decreases the total internal store Ca$^{2+}$ content to 4.8 ± 0.2 a.u. ($n = 69$, $p < 0.001$) in Orai1-overexpressing myotubes, but BTP2 had no effect in myotubes expressing Orai1(E190Q) 6.4 ± 0.3 a.u. ($n = 53$, $p = \text{NS}$).

Western Blot Analyses Performed to Determine Levels of TRPC1, -3, -4, and -6 Expression in WT, JP1 KO, Orai1-overexpressing, and Orai1(E190Q)-expressing Myotubes—In JP1 KO myotubes, TRPC1 (46 ± 5%, $n = 4$) and TRPC3 (21 ± 5%, $n = 4$) expression were significantly reduced, whereas expression of TRPC4 (152 ± 10%, $n = 4$) and TRPC6 (178 ± 9%, $n = 3$) were increased (Fig. 9). All values are expressed as % expression compared with WT myotubes. Orai1-overexpressing cells had a decrease in the expression of TRPC1 (58 ± 13%, $n = 4$), WT levels of TRPC4 (125 ± 10%, $n = 4$) expression and increased expression of both TRPC3 (170 ± 34%, $n = 4$) and TRPC6 (168 ± 22%, $n = 3$). Interestingly, TRPC expression in Orai1(E190Q)-expressing myotubes was similar to WT cells (TRPC1, 90 ± 24%, $n = 4$; TRPC3, 99 ± 15%, $n = 4$; TRPC4, 81 ± 6%, $n = 4$; TRPC6, 90 ± 14, $n = 3$).

DISCUSSION

The mechanisms that regulate the intracellular Ca$^{2+}$ homeostasis in quiescent skeletal muscle are not fully understood. Under resting conditions, any overall passive inward flux from the extracellular space and leak from the SR is compensated by active efflux by the plasma membrane Ca$^{2+}$ ATPase and Na$^{+}$/Ca$^{2+}$ exchanger and Ca$^{2+}$ pumping to the SR by SERCA (Fig. 10, left). Maintaining this equilibrium is essential because chronic Ca$^{2+}$ overload would activate some of the intracellular proteases that can trigger apoptosis (25). On the other hand, the opposite scenario,
chronic Ca\(^{2+}\) depletion, could compromise muscle performance.

Hypothetically, to keep the perfect balance between influx and efflux, this system needs mechanisms to sense and modulate fluxes as is reflected in the stability of the actual values of \([\text{Ca}^{2+}]_{\text{rest}}\). However, the fact that a brief external Ca\(^{2+}\) withdraw is sufficient to affect \([\text{Ca}^{2+}]_{\text{rest}}\) suggests that mechanisms (SERCA, Na\(^{+}\)/Ca\(^{2+}\) exchanger, and plasma membrane Ca\(^{2+}\) ATPase) that have been indicated to be the major contributors are insufficient to explain how this can happen. Thus, it is clear that in addition to what been previously believed, other rapidly responding “on-line” mechanisms must be operating continuously at rest to set the proper \([\text{Ca}^{2+}]_{\text{rest}}\) and the correct loading in the SR.

In this study, we addressed the participation of extracellular Ca\(^{2+}\) influx at rest to maintain the proper \([\text{Ca}^{2+}]_{\text{rest}}\) in the
Orai1 Mediates Resting \([\text{Ca}^{2+}]\) and SR Loading

**FIGURE 5.** Orai1 and Stim1 are dramatically decreased in JP1 KO myotubes. Western blot analysis shows that the expression of Stim1, glycosylated Orai1 (50 kDa), and unglycosylated Orai1 (34 kDa) are strongly decreased in JP1 KO myotubes, whereas JP2 and GAPDH are unchanged compared with WT myotubes (left panel). A densitometric quantification of Western blot against the indicated proteins is shown. Each value was corrected with GAPDH band intensity as a loading correction, and the values are shown as % of the WT intensity (right panel). The dashed line shows the level of expression of WT myotubes.

**FIGURE 6.** SOCE in Orai1-defective myotubes. SOCE was evaluated by a Mn\(^{2+}\) quench technique in myotubes subjected to store depletion as described under “Experimental Procedures.” The arrow indicates the time point when the perfusion system was switched to Mn\(^{2+}\)-containing solution. SOCE signals of WT overexpressing Orai1 and WT myotubes expressing Orai1(E190Q) mutant are shown. Mean traces ± S.E. of at least 15 responses are plotted for each condition.

cytosol and in the SR. We used myotubes that lack the expression of JP1 protein, which has been proposed to be responsible for the interaction between the membranes of the triad junction. If this is the case, the lack of JP1 expression could affect the correct communication between proteins present in the SR membrane and proteins in the T-tubule, and this failure is the presumed explanation for the defect in SOCE demonstrated here and elsewhere (23) in JP1 KO myotubes. Thus, it was not surprising that our results showed that a reduction in SOCE in JP1 myotubes by >60% compared with WT myotubes was accompanied by a reduction in \([\text{Ca}^{2+}]\)\(_{\text{rest}}\).

To further characterize the contributors to the resting \([\text{Ca}^{2+}]\) entry pathway, WT and JP1 KO myotubes were pre-treated with BTP2, a cation entry blocker previously shown to block SOCE in T cells, DT40, and HEK293 cells (26, 27). The exact target of BTP2 is unclear, but it has been shown that it does not interfere with \([\text{Ca}^{2+}]\) ATPase-coupled pumps, mitochondrial \([\text{Ca}^{2+}]\) signaling, endoplasmic reticulum \([\text{Ca}^{2+}]\) release, and K\(^+\) channels in T cells (26). Incubation of myotubes with BTP2 blocks SOCE in WT cells and also eliminates the remaining SOCE in JP1-null myotubes.

In addition, it has been demonstrated that BTP2 blocks Sr\(^{2+}\) entry mediated by TRPC3 expressed in HEK cells when induced by activation of phospholipase C-coupled receptors using carbachol (27). Phospholipase C activation generates diacylglycerol, which is a known agonist of TRPC3 and TRPC6 channels (28). In addition, it has been shown that BTP2 blocks TRPC3 channels activated by the diacylglycerol analog OAG (27). BTP2 has also been shown to block Sr\(^{2+}\) entry through TRPC5 after carbachol stimulation (27), but as TRPC5 is not activated by diacylglycerol, this suggests that BTP2 is a general TRPC blocker regardless of the mechanism of activation.

The channels responsible of SOCE current in skeletal muscle are still controversial (18), but there is compelling data to suggest that Orai1/STIM1 are the major molecular components of SOCE in skeletal muscle (12, 19). BTP2 is very effective (IC\(_{50}\) = 0.1–0.3 \(\mu\)M) in blocking thapsigargin-induced \([\text{Ca}^{2+}]\) entry (27). In this case, the BTP2 target is unknown. The finding that BTP2 “selectively” blocks iCRAC (Ca\(^{2+}\) release-activated Ca\(^{2+}\) current) in lymphocytes (26) and that both BTP2 and expression of the E190Q dominant negative form of Orai1 have a similar effect on SOCE and \(R_{\text{Ca}^{2+}}\) in muscle cells strongly suggest that BTP2 acts on Orai1-mediated \([\text{Ca}^{2+}]\) entry either directly or indirectly through an Orai1-TRPC channel complex rather than through a TRPC channel mechanism alone. Further investigation will be required to directly address the precise mechanism of action of BTP2 on Orai1 channel function.

A different outcome was obtained when we measured Mn\(^{2+}\) entry in cells that were not subjected to \([\text{Ca}^{2+}]\) store depletion where the rate of entry was at least 20 times smaller than cells with empty \([\text{Ca}^{2+}]\) stores. In WT myotubes, the estimated \(R_{\text{Ca}^{2+}}\) was decreased by 50% by BTP2, suggesting an overlapping mechanism between SOCE and \(R_{\text{Ca}^{2+}}\). However, in JP1 KO myotubes, \(R_{\text{Ca}^{2+}}\) is similar to that seen in WT myotubes exposed to BTP2, and further exposure of JP1 KO myotubes to BTP2 has a negligible effect. These data show for the first time that in WT, at least two independent mechanisms work in tandem to control the fine tuning of \(R_{\text{Ca}^{2+}}\): one that is sensitive to BTP2 and another that is refractory BTP2. On the other hand, in JP1 KO myotubes, the primary mechanism for \([\text{Ca}^{2+}]\) entry is via the BTP2-insensitive pathway, whereas the role of the BTP2-sensitive pathway is almost insignificant. In addition, the BTP2-sensitive \([\text{Ca}^{2+}]\) entry pathway is also responsible for fine tuning the \([\text{Ca}^{2+}]\) content of SR, as demonstrated by the fact that JP1 KO myotubes and WT myotubes...
pretreated with BTP2 have less Ca\(^{2+}\) in their stores than untreated WT myotubes.

Western blot analysis clearly shows a significant decrease of Orai1 and Stim1 protein levels in JP1 KO myotubes. This alteration itself could impair the regulatory feedback between Ca\(^{2+}\) stores in the SR and the permeability of the plasma membrane to Ca\(^{2+}\) both at rest and after store depletion. To test this hypothesis, we compared these results with those in cells that overexpressed the pore-defective E190Q Orai1 protein as a dominant negative in WT myotubes. Orai1(E190Q) completely blocks SOCE in cultured myotubes as was previously shown by Lyfenko and Dirksen (12). In addition, Orai1(E190Q) decreases RCaE, the amount of Ca\(^{2+}\) in internal stores and myoplasmic [Ca\(^{2+}\)]\(_{\text{rest}}\), mimicking the JP1 KO phenotype and that of WT myotubes after exposure to BTP2. More importantly, similar to what is seen in JP1 KO myotubes, BTP2 has no effect on reducing [Ca\(^{2+}\)]\(_{\text{rest}}\), maintenance of internal stores, and RCaE in Orai1(E190Q)-expressing myotubes. Thus, these data demonstrate that the BTP2-sensitive...
Orai1 Mediates Resting $[\text{Ca}^{2+}]$ and SR Loading

![Diagram](image)

**FIGURE 10. Participation of Orai1 $\text{Ca}^{2+}$ permeability in resting $\text{Ca}^{2+}$ homeostasis in myotubes.** In resting conditions, the overall passive inward flux from the extracellular (EXT) space is compensated by active efflux. At the same time, $\text{Ca}^{2+}$ that is pumped into the SR should be exactly the same to the $\text{Ca}^{2+}$ that leaks from it, probably through the RyR1 in the leak state. All of these fluxes should be in equilibrium to reach a "normal" and constant $[\text{Ca}^{2+}]$ in the cytosol (Cyt) and in internal stores (left panel). In resting conditions, at least two $\text{Ca}^{2+}$ entry pathways are present in myotubes. One pathway involves the participation of Orai1, and the other is unknown. The ablation or defects of Orai1-mediated $\text{Ca}^{2+}$ entry at rest result in an impaired control of the $\text{Ca}^{2+}$ homeostasis in myotubes at rest, resulting in a decrease in $[\text{Ca}^{2+}]_{\text{rest}}$ and the SR $\text{Ca}^{2+}$ content. This imbalance could be as a result of two phenomena: the decreased $\text{Ca}^{2+}$ influx and the lack of communication between the $\text{Ca}^{2+}$ store levels and the extracellular $\text{Ca}^{2+}$ permeability (right panel). NCX, $\text{Na}^+$/Ca$^{2+}$ exchanger. PMCA, plasma membrane $\text{Ca}^{2+}$ ATPase.

aspect of $R_{\text{Ca}_{\text{ext}}}$ at rest is dependant on Orai1 and suggests that the decreased expression of Orai1 in JP1 KO myotubes or blocking the Orai1-dependent fraction of the $R_{\text{Ca}_{\text{ext}}}$ by BTP2 in WT myotubes leads to altered resting $\text{Ca}^{2+}$ homeostasis. Since TRPCs are known targets of BTP2, the alternative hypothesis was that the unresponsiveness of JP1 KO as well as Orai1(E190Q) myotubes to BTP2 treatment was due to altered expression of TRPCs. Although TRPC1 and TRPC3 expression is reduced in JP1 KO myotubes compared with WT cells, the expression of TRPC4 and TRPC6 (which are similar in structure an function to TRPC1 and TRPC3, respectively) are compensatorily increased, suggesting that low expression of TRPC1 and TRPC3 is not the primary cause of BTP2 unresponsiveness. Furthermore, the fact that Orai1(E190Q)-expressing myotubes are refractory to BTP2 but have a TRPC expression profile that is almost identical to WT cells suggests that changes in TRPC expression cannot account for the alterations in resting $\text{Ca}^{2+}$ homeostasis that we observed.

In a previous report (23), it was shown that in muscle fibers in which adenoviral-shRNA was used to knock down both JP1 and JP2 decreases both SOCE and SR $\text{Ca}^{2+}$ content in agreement with this work. However, these results differ with our study in that a slight increase in the basal Fura2 F340/F360 ratio in muscle cells treated with shRNA compared with controls was found. At first, this last result could appear to be contradictory with the present work, but these results are not comparable because JP2 expression was not altered in the current study. The simultaneous knockdown of JP1 and JP2 proteins may cause additional alterations in $\text{Ca}^{2+}$-handling proteins that could shift the $[\text{Ca}^{2+}]$ equilibrium at rest to higher levels in the cytosol, which could explain the previously observed small increase in resting $\text{Ca}^{2+}$. In addition, in the present study, calibrated microelectrodes were used, which is a much more precise and exact method to determine resting $[\text{Ca}^{2+}]$. These electrodes allow discrimination of differences in $[\text{Ca}^{2+}]$ of $<5$ nM in the linear portion of the curve response ($p\text{Ca}3–7$), which gives further confidence that the differences that we observed are correct.

In summary, our data show that under resting conditions at least two $\text{Ca}^{2+}$ entry pathways are present in myotubes. One of these pathways involves the participation of Orai1, which is sensitive to BTP2. The ablation of Orai1-mediated $R_{\text{Ca}_{\text{ext}}}$ results in an impaired control of the $\text{Ca}^{2+}$ homeostasis in myotubes, resulting in a decrease in $[\text{Ca}^{2+}]_{\text{rest}}$ and SR $\text{Ca}^{2+}$ content (Fig. 10, right panel).

REFERENCES

1. López, J. R., Contreras, J., Linares, N., and Allen, P. D. (2000) *Anesthesiology* **92**, 1799–1806
2. Yang, T., Esteve, E., Pessah, I. N., Molinski, T. F., Allen, P. D., and López, J. R. (2007) *Am. J. Physiol. Cell Physiol.* **292**, C1591–1598
3. Eltit, J. M., Yang, T., Li, H., Molinski, T. F., Pessah, I. N., Allen, P. D., and Lopez, J. R. (2010) *J. Biol. Chem.* **285**, 13781–13787
4. López, J. R., Alamo, L., Caputo, C., DiPolo, R., and Vergara, S. (1983) *Biophys. J.* **43**, 1–4
5. Kurebayashi, N., and Ogawa, Y. (2001) *J. Physiol.* **533**, 185–199
6. Pan, Z., Yang, D., Nagaraj, R. Y., Nosek, T. A., Nishi, M., Takeshima, H., Cheng, H., and Ma, J. (2002) *Nat. Cell Biol.* **4**, 379–383
7. Roos, J., DiGregorio, P. J., Yeromin, A. V., Ohlsen, K., Lioudyno, M.,
Orai1 Mediates Resting $[Ca^{2+}]$ and SR Loading

Zhang, S., Safrina, O., Kozak, J. A., Wagner, S. L., Cahalan, M. D., Veliccebi, G., and Stauderman, K. A. (2005) J. Cell Biol. 169, 435–445

8. Soboloff, J., Spassova, M. A., Tang, X. D., Hewavitharana, T., Xu, W., and Gill, D. L. (2006) J. Biol. Chem. 281, 20661–20665

9. Feske, S., Gwack, Y., Prakriya, M., Srikanth, S., Puppel, S. H., Tanasa, B., Hogan, P. G., Lewis, R. S., Daly, M., and Rao, A. (2006) Nature 441, 179–185

10. Vig, M., Peinelt, C., Beck, A., Koomoa, D. L., Rabah, D., Koblan-Huberson, M., Kraft, S., Turner, H., Fleig, A., Penner, R., and Kinet, J. P. (2006) Science 312, 1220–1223

11. Prakriya, M., Feske, S., Gwack, Y., Srikanth, S., Rao, A., and Hogan, P. G. (2006) Nature 443, 230–233

12. Lyfenko, A. D., and Dirksen, R. T. (2008) J. Physiol. 586, 4815–4824

13. Liao, Y., Erxleben, C., Abramowitz, J., Flockerzi, V., Zhu, M. X., Armstrong, D. L., and Birnbaumer, L. (2008) Proc. Natl. Acad. Sci. U.S.A. 105, 2895–2900

14. Liao, Y., Erxleben, C., Yildirim, E., Abramowitz, J., Armstrong, D. L., and Birnbaumer, L. (2007) Proc. Natl. Acad. Sci. U.S.A. 104, 4682–4687

15. Yuan, J. P., Zeng, W., Huang, G. N., Worley, P. F., and Muallem, S. (2007) Nat. Cell Biol. 9, 636–645

16. Ong, H. L., Cheng, K. T., Liu, X., Bandypadhyay, B. C., Paria, B. C., Soboloff, J., Pani, B., Gwack, Y., Srikanth, S., Singh, B. B., Gill, D. L., Gill, D., and Ambudkar, I. S. (2007) J. Biol. Chem. 282, 9105–9116

17. Brandman, O., Liou, J., Park, W. S., and Meyer, T. (2007) Cell 131, 1327–1339

18. Shin, D. M., and Muallem, S. (2008) Nat. Cell Biol. 10, 639–641

19. Stiber, J., Hawkins, A., Zhang, Z. S., Wang, S., Burch, J., Graham, V., Ward, C. C., Seth, M., Finch, E., Malouf, N., Williams, R. S., Eu, J. P., and Rosenberg, P. (2008) Nat. Cell Biol. 10, 688–697

20. Vandebroucke, C., Martin, D., Colson-Van Schoor, M., Debaix, H., and Gailly, P. (2002) J. Cell Biol. 158, 1089–1096

21. Ito, K., Komazaki, S., Sasamoto, K., Yoshida, M., Nishii, M., Kitamura, K., and Takeshima, H. (2001) J. Cell Biol. 154, 1059–1067

22. Komazaki, S., Ito, K., Takeshima, H., and Nakamura, H. (2002) FEBS Lett. 524, 225–229

23. Hirata, Y., Brotto, M., Weisleder, N., Chu, Y., Lin, P., Zhao, X., Thornton, A., Komazaki, S., Takeshima, H., Ma, J., and Pan, Z. (2006) Biophys. J. 90, 4418–4427

24. Perez, C. F., Lopez, J. R., and Allen, P. D. (2005) Am. J. Physiol. Cell Physiol. 288, C640–649

25. MacLennan, D. H. (2000) Eur. J. Biochem. 267, 5291–5297

26. Zitt, C., Strauss, B., Schwarz, E. C., Spaeth, N., Rast, G., Hatzelmann, A., and Hoth, M. (2004) J. Biol. Chem. 279, 12427–12437

27. He, L. P., Hewavitharana, T., Soboloff, J., Spassova, M. A., and Gill, D. L. (2005) J. Biol. Chem. 280, 10997–11006

28. Hofmann, T., Obukhov, A. G., Schaefer, M., Harteneck, C., Gudermann, T., and Schultz, G. (1999) Nature 397, 259–263

29. Lee, K. P., Yuan, J. P., Hong, J. H., So, I., Worley, P. F., and Muallem, S. (2010) FEBS Lett. 584, 2022–2027

30. Clapham, D. E., Julius, D., Montell, C., and Schultz, G. (2005) Pharmacol. Rev. 57, 427–450

31. Mery, L., Magnino, F., Schmidt, K., Krause, K. H., and Dufour, J. F. (2001) FEBS Lett. 487, 377–383